Table 2 Summary of tumor characteristics and treatment parameters

Number of patients

147

Sex

 Female

39 (26.6%)

 Male

108 (73.4%)

Age

 Median (range)

75.6 (70–86)

 70 - 75

80 (54.4%)

 >75

67 (45.6%)

Signs and symptoms

 Mental status change

10 (6.8%)

 Dizziness

12 (8.2%)

 Motor/sensory deficit

40 (27.3%)

 Gait disturbance

1 (0.7%)

 Headache

27 (18.3%)

 Nausea & vomiting

2 (1.3%)

 Swallowing difficulty

2 (1.3%)

 Incidental detect

53 (36.1%)

Karnofsky Performance Status (KPS)

 Median (range)

84 (40–100)

 ≤60

21 (14.2%)

 70-80

41 (28.0%)

 90≤

85 (57.8%)

Primary tumor

 Lung cancer

111 (75.5%)

 Rectal cancer

7 (4.7%)

 Colon cancer

6 (4.0%)

 Gastric cancer

3 (2.0%)

 Breast cancer

6 (4.0%)

 Cervix cancer

1 (0.6%)

 Gall bladder cancer

2 (1.2%)

 Hepatic cancer

1 (0.6%)

 Renal cancer

2 (1.2%)

 Pancreas cancer

1 (0.6%)

 Melanoma

2 (1.2%)

 Prostate cancer

1 (0.6%)

 Esophageal cancer

1 (0.6%)

 Not confirmed

3 (2.0%)

Primary cancer status

 Progression disease

102 (69.4%)

 Stable, partial regression

40 (27.2%)

 Complete regression

5 (3.4%)

Extracranial metastasis

 Yes

91 (61.9%)

 No

56 (38.1%)

 Metachronous

82 (55.8%)

 Synchronous

65 (44.2%)

Number of metastasis

 Median (range)

2.0 (1–12)

 Single

61 (41.5%)

 2 - 5

58 (39.5%)

 >6

28 (19.0%)

Largest lesion volume (cc)

 Median (range)

5.1 (0.05-59.9)

 <5

71 (48.3%)

 5-13

55 (37.4%)

 13<

21 (14.3%)

Infratentorial/brain stem

Involvement

 No

95 (64.6%)

 Yes

52 (35.4%)

Following WBRT

 Yes

13 (8.9%)

 No

134 (91.1%)

Sequential systemic chemotherapy

 Yes

55 (37.4%)

 No

92 (62.6%)

SIRS score

 Median

4.0

 0 - 3

42 (28.6%)

 4 - 7

105 (71.4%)

GPA score

 Median

1.5

 0 - 1.5

77 (52.4%)

 2 - 4

70 (47.6%)

RPA class

 II

126 (85.7%)

 III

21 (14.3%)

BSBM score

 0 - 1

58 (39.5%)

 2 - 3

89 (60.5%)